Parnax Lab profit and loss

Latest FY25

Revenue: ₹7.0cr−5.7% on FY24
EBITDA: ₹1.2cr−41.5% on FY24

₹ crore except per share

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022	FY21 and earlierAlpha Plus

Expenses
	7.0	7.4	7.5	7.1	FY21 and earlierEvery year the company has filed comes with Alpha Plus.
	0.7	0.5	0.4	0.2
	1.1	2.3	1.9	1.9
	1.8	0.7	1.6	1.5
	0.1	—	—	—
	0.9	0.7	0.6	0.5
	0.0	0.1	0.2	0.7
	0.1	0.1	0.1	0.0
	1.9	1.6	1.9	1.9
	5.9	5.5	6.2	6.5
	1.2	2.1	1.6	1.4
	1.2	2.1	1.5	1.3
Profit
	1.9	2.4	1.6	0.8
	0.5	0.6	0.4	0.2
	0.5	0.6	0.4	0.2
	−0.0	−0.0	−0.1	−0.0
	1.4	1.8	1.2	0.5
Per share
	₹1.21	₹1.59	₹1.09	₹0.64
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	4.0	4.4	4.0	3.8
	57.3%	59.7%	53.5%	52.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

PARNAXLAB₹103.25

Parnax Lab Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL NOVARTIND SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
Revenue from Operations	7.1	7.5	7.4	7.0
Other Income	0.2	0.4	0.5	0.7
Expenses
+ Cost of Materials Consumed	1.9	1.9	2.3	1.1
+ Purchases of Stock-in-Trade	1.5	1.6	0.7	1.8
+ Changes in Inventories	—	—	—	0.1
+ Employee Benefit Expense	0.5	0.6	0.7	0.9
+ Finance Costs	0.7	0.2	0.1	0.0
+ Depreciation & Amortisation	0.0	0.1	0.1	0.1
+ Other Expenses	1.9	1.9	1.6	1.9
Total Expenses	6.5	6.2	5.5	5.9
EBITDA	1.4	1.6	2.1	1.2
EBIT	1.3	1.5	2.1	1.2
Profit
Pretax Income	0.8	1.6	2.4	1.9
+ Deferred Tax	0.2	0.4	0.6	0.5
Tax Expense	0.2	0.4	0.6	0.5
+ Other Comprehensive Income	-0.0	-0.1	-0.0	-0.0
Total Comprehensive Income	0.5	1.2	1.8	1.4
Per Share
Basic EPS	0.64	1.09	1.59	1.21
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3.8	4.0	4.4	4.0
Gross Margin %	52.64	53.51	59.70	57.25

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.